EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 / No 5 (Mai 2025) Med Sci (Paris), 41 5 (2025) 425-433 References
Open Access
Issue
Med Sci (Paris)
Volume 41, Number 5, Mai 2025
Enjeux et objectifs de la psychiatrie de précision
Page(s) 425 - 433
Section La psychiatrie de précision (PEPR PROPSY) : hypothèses et outils
DOI https://doi.org/10.1051/medsci/2025062
Published online 26 May 2025
  1. Saleh Y, Jarratt-Barnham I, Fernandez-Egea E, Husain M. Mechanisms underlying motivational dysfunction in schizophrenia. Front Behav Neurosci 2021 ; 15 : 709753. [CrossRef] [PubMed] [Google Scholar]
  2. Ribot T. La psychologie des sentiments. Paris : Félix Alcan, 1896. [Google Scholar]
  3. Rømer Thomsen K, Whybrow PC, Kringelbach ML. Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain. Front Behav Neurosci 2015 ; 9 : 49. [CrossRef] [PubMed] [Google Scholar]
  4. Kangas BD, Der-Avakian A, Pizzagalli DA. Probabilistic reinforcement learning and anhedonia. Curr Top Behav Neurosci 2022 ; 58 : 355–77. [CrossRef] [PubMed] [Google Scholar]
  5. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010 ; 167 : 7 48–51. [Google Scholar]
  6. Demazeux S, Pidoux V. Le projet RDoC - La classification psychiatrique de demain ? Med Sci (Paris) 2015 ; 31 : 792–6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Lambert C, Da Silva S, Ceniti AK, et al. Anhedonia in depression and schizophrenia: a transdiagnostic challenge. CNS Neurosci Ther 2018 ; 24 : 615–23. [CrossRef] [PubMed] [Google Scholar]
  8. Nusslock R, Alloy LB. Reward processing and mood-related symptoms: an RDoC and translational neuroscience perspective. J Affect Disord 2017 ; 216 : 3–16. [CrossRef] [PubMed] [Google Scholar]
  9. Han GT, Tomarken AJ, Gotham KO. Social and non-social reward moderate the relation between autism symptoms and loneliness in adults with ASD, depression, and controls. Autism Res 2019 ; 12 : 884. [CrossRef] [PubMed] [Google Scholar]
  10. Auerbach RP, Pagliaccio D, Kirshenbaum JS. Anhedonia and suicide. In: Pizzagalli DA, ed. Anhedonia: preclinical, translational, and clinical integration. Cham : Springer International Publishing, 2022 : 443–64. [CrossRef] [PubMed] [Google Scholar]
  11. Klein ME, Grice AB, Sheth S, et al. Pharmacological treatments for anhedonia. Curr Top Behav Neurosci 2022 ; 58 : 467–89. [CrossRef] [PubMed] [Google Scholar]
  12. Sandman CF, Craske MG. Psychological treatments for anhedonia. Curr Top Behav Neurosci 2022 ; 58 : 491–513. [CrossRef] [PubMed] [Google Scholar]
  13. Siddiqi SH, Haddad N, Fox MD. Circuit-targeted neuromodulation for anhedonia. In: Pizzagalli DA, ed. Anhedonia: preclinical, translational, and clinical integration. Cham : Springer International Publishing, 2022 : 515–35. [CrossRef] [PubMed] [Google Scholar]
  14. Dimick MK, Hird MA, Fiksenbaum LM, et al. Severe anhedonia among adolescents with bipolar disorder is common and associated with increased psychiatric symptom burden. J Psychiatr Res 2021 ; 134 : 200–7. [CrossRef] [PubMed] [Google Scholar]
  15. Wong S, Le GH, Phan L, et al. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: a systematic review and meta-analysis. J Affect Disord 2024 ; 356 : 684–98. [CrossRef] [PubMed] [Google Scholar]
  16. Whitton AE, Kumar P, Treadway MT, et al. Distinct profiles of anhedonia and reward processing and their prospective associations with quality of life among individuals with mood disorders. Mol Psychiatry 2023 ; 28 : 5272–81. [CrossRef] [PubMed] [Google Scholar]
  17. Herbener ES, Harrow M, Hill SK. Change in the relationship between anhedonia and functional deficits over a 20-year period in individuals with schizophrenia. Schizophr Res 2005 ; 75 : 97–105. [CrossRef] [PubMed] [Google Scholar]
  18. Pelizza L, Garlassi S, Azzali S, et al. Anhedonia in young people with first episode psychosis: a longitudinal study. Nord J Psychiatry 2020 ; 74 : 381–9. [CrossRef] [PubMed] [Google Scholar]
  19. Birnie MT, Levis SC, Mahler SV, et al. Developmental trajectories of anhedonia in preclinical models. Curr Top Behav Neurosci 2022 ; 58 : 23–41. [CrossRef] [PubMed] [Google Scholar]
  20. Bouc RL, Pessiglione M. La motivation dans tous ses K - Approche computationnelle des pathologies neuropsychiatriques. Med Sci (Paris) 2018 ; 34 : 238–46. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  21. Bickel WK, Johnson MW, Koffarnus MN, et al. The behavioral economics of substance use disorders: reinforcement pathologies and their repair. Annu Rev Clin Psychol 2014 ; 10 : 641–77. [CrossRef] [PubMed] [Google Scholar]
  22. Levis SC, Bentzley BS, Molet J, et al. On the early life origins of vulnerability to opioid addiction. Mol Psychiatry 2021 ; 26 : 4409–16. [CrossRef] [PubMed] [Google Scholar]
  23. Hardin-Pouzet H, Morosan S. Des souris, des rats et des hommes - En quoi les modèles rongeurs restent indispensables pour la production de connaissances. Med Sci (Paris) 2019 ; 35 : 479–82. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 2011 ; 35 : 537–55. [CrossRef] [PubMed] [Google Scholar]
  25. Favier M, Carcenac C, Savasta M, et al. Motivation et apathie parkinsonienne - Rôle des récepteurs dopaminergiques RD3. Med Sci (Paris) 2017 ; 33 : 822–4. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  26. Cannon CM, Palmiter RD. Reward without dopamine. J Neurosci 2003 ; 23 : 10827–31. [CrossRef] [PubMed] [Google Scholar]
  27. Salamone JD, Correa M, Farrar A, et al. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl) 2007 ; 191 : 461–82. [CrossRef] [PubMed] [Google Scholar]
  28. Bardgett ME, Depenbrock M, Downs N, et al. Dopamine modulates effort-based decision making in rats. Behav Neurosci 2009 ; 123 : 242–51. [CrossRef] [PubMed] [Google Scholar]
  29. Treadway MT, Salamone JD. Vigor, effort-related aspects of motivation and anhedonia. Curr Top Behav Neurosci 2022 ; 58 : 325–53. [CrossRef] [PubMed] [Google Scholar]
  30. Kranz GS, Kasper S, Lanzenberger R. Reward and the serotonergic system. Neuroscience 2010 ; 166 : 1023–35. [CrossRef] [PubMed] [Google Scholar]
  31. Lucido MJ, Bekhbat M, Goldsmith DR, et al. Aiding and abetting anhedonia: impact of inflammation on the brain and pharmacological implications. Pharmacol Rev 2021 ; 73 : 1084–117. [CrossRef] [PubMed] [Google Scholar]
  32. Singh B, Vande Voort JL, Riva-Posse P, et al. Ketamine-associated change in anhedonia and mTOR expression in treatment-resistant depression. Biol Psychiatry 2023 ; 93 : e65–8. [CrossRef] [PubMed] [Google Scholar]
  33. Eichwald T, da Silva L de B, Staats Pires AC, et al. Tetrahydrobiopterin: beyond its traditional role as a cofactor. Antioxidants 2023 ; 12 : 1037. [CrossRef] [PubMed] [Google Scholar]
  34. Juárez Olguín H, Calderón Guzmán D, Hernández García E, et al. The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid Med Cell Longev 2016 ; 2016 : 9730467. [CrossRef] [PubMed] [Google Scholar]
  35. Lapidus KAB, Gabbay V, Mao X, et al. In vivo 1H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neurosci Lett 2014 ; 569 : 74–9. [CrossRef] [PubMed] [Google Scholar]
  36. Jordan B. Chroniques génomiques - Épigénétique et résilience. Med Sci (Paris) 2013 ; 29 : 325–8. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  37. Cunningham S, Mazurka R, Wynne-Edwards KE, et al. Cortisol reactivity to stress predicts behavioral responsivity to reward moderation by sex, depression, and anhedonia. J Affect Disord 2021 ; 293 : 1–8. [CrossRef] [PubMed] [Google Scholar]
  38. Chumbley JR, Hulme O, Köchli H, et al. Stress and reward: long term cortisol exposure predicts the strength of sexual preference. Physiol Behav 2014 ; 131 : 33–40. [CrossRef] [PubMed] [Google Scholar]
  39. Lesiak AJ, Coffey K, Cohen JH, et al. Sequencing the serotonergic neuron translatome reveals a new role for Fkbp5 in stress. Mol Psychiatry 2021 ; 26 : 4742–53. [CrossRef] [PubMed] [Google Scholar]
  40. Debs SR, Rothmond DA, Zhu Y, et al. Molecular evidence of altered stress responsivity related to neuroinflammation in the schizophrenia midbrain. J Psychiatr Res 2024 ; 177 : 118–28. [CrossRef] [PubMed] [Google Scholar]
  41. Borsini A, Wallis ASJ, Zunszain P, et al. Characterizing anhedonia: a systematic review of neuroimaging across the subtypes of reward processing deficits in depression. Cogn Affect Behav Neurosci 2020 ; 20 : 816–41. [CrossRef] [PubMed] [Google Scholar]
  42. Carlezon Jr WA, Krystal AD. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress Anxiety 2016 ; 33 : 895–906. [CrossRef] [PubMed] [Google Scholar]
  43. Ward J, Lyall LM, Bethlehem RAI, et al. Novel genome-wide associations for anhedonia, genetic correlation with psychiatric disorders, and polygenic association with brain structure. Transl Psychiatry 2019 ; 9 : 1–9. [CrossRef] [PubMed] [Google Scholar]
  44. Zhu X, Ward J, Cullen B, et al. Phenotypic and genetic associations between anhedonia and brain structure in UK Biobank. Transl Psychiatry 2021 ; 11 : 1–8. [CrossRef] [PubMed] [Google Scholar]
  45. Kennerley SW, Behrens TEJ, Wallis JD. Double dissociation of value computations in orbitofrontal and anterior cingulate neurons. Nat Neurosci 2011 ; 14 : 1581–9. [CrossRef] [PubMed] [Google Scholar]
  46. Hyman JM, Holroyd CB, Seamans JK. A novel neural prediction error found in anterior cingulate cortex ensembles. Neuron 2017 ; 95 : 447–56e3. [CrossRef] [PubMed] [Google Scholar]
  47. Cardinal RN, Howes NJ. Effects of lesions of the nucleus accumbens core on choice between small certain rewards and large uncertain rewards in rats. BMC Neurosci 2005 ; 6 : 37. [CrossRef] [PubMed] [Google Scholar]
  48. Harkness KL, Lamontagne SJ, Cunningham S. Environmental contributions to anhedonia. Curr Top Behav Neurosci 2022 ; 58 : 81–108. [CrossRef] [PubMed] [Google Scholar]
  49. Ventorp F, Lindahl J, van Westen D, et al. Preliminary evidence of efficacy and target engagement of pramipexole in anhedonic depression. Psychiatr Res Clin Pract 2022 ; 4 : 42–7. [CrossRef] [PubMed] [Google Scholar]
  50. Bekhbat M, Li Z, Mehta ND, et al. Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Mol Psychiatry 2022 ; 27 : 4113–21. [CrossRef] [PubMed] [Google Scholar]
  51. Treadway MT, Etuk SM, Cooper JA, et al. A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation. Mol Psychiatry 2025 ; 30 : 1407–17. [CrossRef] [PubMed] [Google Scholar]
  52. Drevets WC, Wittenberg GM, Bullmore ET, et al. Immune targets for therapeutic development in depression: towards precision medicine. Nat Rev Drug Discov 2022 ; 21 : 224–44. [CrossRef] [PubMed] [Google Scholar]
  53. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016 ; 3 : 619–27. [CrossRef] [PubMed] [Google Scholar]
  54. Cao B, Zhu J, Zuckerman H, et al. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 2019 ; 92 : 109–17. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.